Prescribing information


Cosentyx is indicated for the treatment of: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy; active psoriatic arthritis in adult patients, alone or in combination with MTX, when the response to previous DMARD therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated CRP and/or MRI evidence in adults who have responded inadequately to NSAIDs.

Explore our resources designed to support Cosentyx initiation and ongoing maintenance for patients with plaque psoriasis.

You can download certain files below for you to share with your Cosentyx patients separately. Do not share links to this website or screenshots with patients as this website is intended for healthcare professionals only.

Please note that these resources are designed for optimal use on desktop or tablet. Functionality may be restricted on some devices, including mobile.


Image of Cosentyx digital patient pack

Digital patient pack

This interactive PDF contains everything your patients need to get going with treatment and to help them get the most out of it.


patient 300mg alert leaflet

300mg Patient alert leaflet

A short booklet containing information that your patients need to know in regards to the new UnoReady® 300mg injection pen.



Image of Cosentyx digital patient leaflet

Digital dosing schedule

​An interactive PDF to help your newly initiated Cosentyx patients keep track of their treatment.



Image of Cosentyx digital dosing schedule

SensoReady® 150mg injection video

A short instructional video that demonstrates how to prepare and inject Cosentyx with the SensoReady® 150mg pen.

See more

Image of UnoReady injection video

UnoReady® 300mg injection video

A short video showing you how to prepare and inject Cosentyx with the UnoReady® 300mg pen..

See more



CRP, C-reactive protein; DMARD, disease-modifying anti-rheumatic drug; MRI, magnetic resonance imaging; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs.

Rate this content: 
No votes yet
UK | April 2021 | 117276

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]